Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-03-03

AUTHORS

Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski, David I. Quinn, Olga Castellanos, Patrick Gilmore, Jean C. Shih

ABSTRACT

PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and PSA 4.7 ± 5.8 ng/dl. Maximal PSA declines ≥30% and ≥50% were observed in 25% (n = 5/20) and 10% (n = 2/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines ≥30% and ≥50% of 24% (n = 4/17) and 6% (n = 1/17), respectively. Common toxicities observed included dizziness (grade 1 = 45%, grade 2 = 35%), hypertension (grade ≥ 2 = 30%), and edema (grade 1 = 25%, grade 2 = 10%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer. More... »

PAGES

61-68

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9

DOI

http://dx.doi.org/10.1038/s41391-020-0211-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1125322716

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32123315


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Monoamine Oxidase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenelzine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488628.8", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gross", 
        "givenName": "Mitchell E.", 
        "id": "sg:person.0623540223.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488628.8", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agus", 
        "givenName": "David B.", 
        "id": "sg:person.01130633732.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130633732.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488628.8", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "Tanya B.", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488628.8", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinski", 
        "givenName": "Jacek K.", 
        "id": "sg:person.0600562331.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.488628.8", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castellanos", 
        "givenName": "Olga", 
        "id": "sg:person.015566147707.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566147707.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilmore", 
        "givenName": "Patrick", 
        "id": "sg:person.010167317465.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010167317465.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Integrative Anatomical Sciences, University of Southern California, Los Angeles, CA, USA", 
            "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shih", 
        "givenName": "Jean C.", 
        "id": "sg:person.07360615242.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07360615242.02"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrn1883", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004025765", 
          "https://doi.org/10.1038/nrn1883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41388-018-0325-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104267265", 
          "https://doi.org/10.1038/s41388-018-0325-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-03-03", 
    "datePublishedReg": "2020-03-03", 
    "description": "PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA\u2009\u2265\u20090.4\u2009ng/ml (post prostatectomy) or PSA\u2009\u2265\u20092\u2009ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30\u2009mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of \u226550% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean\u2009\u00b1\u2009SD age 66.9\u2009\u00b1\u20094.8 years and PSA 4.7\u2009\u00b1\u20095.8\u2009ng/dl. Maximal PSA declines \u226530% and \u226550% were observed in 25% (n\u2009=\u20095/20) and 10% (n\u2009=\u20092/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines \u226530% and \u226550% of 24% (n\u2009=\u20094/17) and 6% (n\u2009=\u20091/17), respectively. Common toxicities observed included dizziness (grade 1\u2009=\u200945%, grade 2\u2009=\u200935%), hypertension (grade \u2265\u20092\u2009=\u200930%), and edema (grade 1\u2009=\u200925%, grade 2\u2009=\u200910%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41391-020-0211-9", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438805", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5477093", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1119336", 
        "issn": [
          "1365-7852", 
          "1476-5608"
        ], 
        "name": "Prostate Cancer and Prostatic Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "recurrent prostate cancer", 
      "biochemical recurrent prostate cancer", 
      "prostate cancer", 
      "open-label single-arm clinical trial", 
      "Most treatment-related toxicities", 
      "single-arm clinical trial", 
      "monoamine oxidase inhibitor phenelzine", 
      "normal androgen levels", 
      "Depression Score questionnaires", 
      "grade 4 hypertension", 
      "treatment-related toxicity", 
      "evidence of metastasis", 
      "proportion of patients", 
      "phase 2 trial", 
      "effects of phenelzine", 
      "arm clinical trial", 
      "pre-clinical models", 
      "PSA decline", 
      "eligible patients", 
      "common toxicities", 
      "primary endpoint", 
      "treatment discontinuation", 
      "HADS questionnaire", 
      "score questionnaire", 
      "cardiovascular toxicity", 
      "clinical trials", 
      "androgen levels", 
      "mood symptoms", 
      "depressive symptoms", 
      "patients", 
      "cancer growth", 
      "cancer", 
      "PSA", 
      "significant decrease", 
      "hypertension", 
      "phenelzine", 
      "metastasis", 
      "symptoms", 
      "treatment", 
      "trials", 
      "subjects", 
      "toxicity", 
      "episodes", 
      "questionnaire", 
      "dizziness", 
      "discontinuation", 
      "edema", 
      "syncope", 
      "ResultsCharacteristics", 
      "therapy", 
      "dl", 
      "baseline", 
      "endpoint", 
      "weeks", 
      "efficacy", 
      "anxiety", 
      "MAOA", 
      "years", 
      "proportion", 
      "new avenues", 
      "evidence", 
      "levels", 
      "decline", 
      "decrease", 
      "effect", 
      "changes", 
      "avenues", 
      "growth", 
      "model", 
      "materials"
    ], 
    "name": "Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer", 
    "pagination": "61-68", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1125322716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41391-020-0211-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32123315"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41391-020-0211-9", 
      "https://app.dimensions.ai/details/publication/pub.1125322716"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_867.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41391-020-0211-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      115 URIs      105 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41391-020-0211-9 schema:about N020a7fa06dfd41a79f95c00590f30202
2 N06408a2563d1442ca36b5b5a7bc61d9d
3 N1fba275e8c704b779863ff88873ea55a
4 N304a976efd3f47dfa71160773a65c6a6
5 N37008aaa99b44b108a5fde4481a97b72
6 N60744ec6fc994875acc9e23c2d0663b0
7 N6dfdc6e93ddf4a658325855842e74605
8 N84ed7968eb5c414086f597ab1bc6c9fd
9 N86f14fab5f924e1ba77a95900daf33eb
10 N9135111f812b4b5c95d020834c7751a2
11 Na2f6b0831fa445f4b66a244367c36871
12 Naf47afb6c62241d78bf168c86762772a
13 Nbe32a2262f5a41b5be038a045d8ef090
14 Nc065564811414645a40fa76aead078c9
15 Nc6a688e6f0854e33ba66fdf5febc07f5
16 Nca9cd693b1b644c4847c1a89f0b8a76f
17 Ncdc2787cf63a4210a638871082793966
18 Nfb21a6044a444275a7a945a46ffe476f
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nc6e0c831680c4361a90aa2792a1cf25c
22 schema:citation sg:pub.10.1038/nrn1883
23 sg:pub.10.1038/s41388-018-0325-x
24 schema:datePublished 2020-03-03
25 schema:datePublishedReg 2020-03-03
26 schema:description PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and PSA 4.7 ± 5.8 ng/dl. Maximal PSA declines ≥30% and ≥50% were observed in 25% (n = 5/20) and 10% (n = 2/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines ≥30% and ≥50% of 24% (n = 4/17) and 6% (n = 1/17), respectively. Common toxicities observed included dizziness (grade 1 = 45%, grade 2 = 35%), hypertension (grade ≥ 2 = 30%), and edema (grade 1 = 25%, grade 2 = 10%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N480543849fd04c9b9a6e579e0079437f
30 N5663ec49d37b4f2a9e6c0eaa6ae6b32b
31 sg:journal.1119336
32 schema:keywords Depression Score questionnaires
33 HADS questionnaire
34 MAOA
35 Most treatment-related toxicities
36 PSA
37 PSA decline
38 ResultsCharacteristics
39 androgen levels
40 anxiety
41 arm clinical trial
42 avenues
43 baseline
44 biochemical recurrent prostate cancer
45 cancer
46 cancer growth
47 cardiovascular toxicity
48 changes
49 clinical trials
50 common toxicities
51 decline
52 decrease
53 depressive symptoms
54 discontinuation
55 dizziness
56 dl
57 edema
58 effect
59 effects of phenelzine
60 efficacy
61 eligible patients
62 endpoint
63 episodes
64 evidence
65 evidence of metastasis
66 grade 4 hypertension
67 growth
68 hypertension
69 levels
70 materials
71 metastasis
72 model
73 monoamine oxidase inhibitor phenelzine
74 mood symptoms
75 new avenues
76 normal androgen levels
77 open-label single-arm clinical trial
78 patients
79 phase 2 trial
80 phenelzine
81 pre-clinical models
82 primary endpoint
83 proportion
84 proportion of patients
85 prostate cancer
86 questionnaire
87 recurrent prostate cancer
88 score questionnaire
89 significant decrease
90 single-arm clinical trial
91 subjects
92 symptoms
93 syncope
94 therapy
95 toxicity
96 treatment
97 treatment discontinuation
98 treatment-related toxicity
99 trials
100 weeks
101 years
102 schema:name Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer
103 schema:pagination 61-68
104 schema:productId N713c40a25a8b4eec8775fa4904f3076d
105 N951d18f1de1b4f708d04d5afe00f31da
106 Ndbccb2ff16784c1bb98336a2f2e4c13f
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125322716
108 https://doi.org/10.1038/s41391-020-0211-9
109 schema:sdDatePublished 2022-12-01T06:41
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N9c387d24a5234a87a0d21932f580cc70
112 schema:url https://doi.org/10.1038/s41391-020-0211-9
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N020a7fa06dfd41a79f95c00590f30202 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Dose-Response Relationship, Drug
118 rdf:type schema:DefinedTerm
119 N06408a2563d1442ca36b5b5a7bc61d9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Biomarkers, Tumor
121 rdf:type schema:DefinedTerm
122 N09787571bc8e4daf9838f6aaf36cd1f9 rdf:first sg:person.07360615242.02
123 rdf:rest rdf:nil
124 N1b637233cce044d1b1c4b6721cb80486 rdf:first sg:person.01007666002.23
125 rdf:rest Ne149427eb1f345f2a813134505dd6ba3
126 N1fba275e8c704b779863ff88873ea55a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Prostate-Specific Antigen
128 rdf:type schema:DefinedTerm
129 N304a976efd3f47dfa71160773a65c6a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Treatment Outcome
131 rdf:type schema:DefinedTerm
132 N3631b287d1104f63b1d931eb1c8a1e04 rdf:first sg:person.01013134010.15
133 rdf:rest Nd4b7a58fe3fa4bdd92fd504185f2276c
134 N37008aaa99b44b108a5fde4481a97b72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Male
136 rdf:type schema:DefinedTerm
137 N480543849fd04c9b9a6e579e0079437f schema:issueNumber 1
138 rdf:type schema:PublicationIssue
139 N5663ec49d37b4f2a9e6c0eaa6ae6b32b schema:volumeNumber 24
140 rdf:type schema:PublicationVolume
141 N60744ec6fc994875acc9e23c2d0663b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Adenocarcinoma
143 rdf:type schema:DefinedTerm
144 N6dfdc6e93ddf4a658325855842e74605 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N713c40a25a8b4eec8775fa4904f3076d schema:name dimensions_id
148 schema:value pub.1125322716
149 rdf:type schema:PropertyValue
150 N71ae5b286b4e430c88eac19d54620597 rdf:first sg:person.010167317465.06
151 rdf:rest N09787571bc8e4daf9838f6aaf36cd1f9
152 N84ed7968eb5c414086f597ab1bc6c9fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Phenelzine
154 rdf:type schema:DefinedTerm
155 N86f14fab5f924e1ba77a95900daf33eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Follow-Up Studies
157 rdf:type schema:DefinedTerm
158 N9135111f812b4b5c95d020834c7751a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Neoplasm Recurrence, Local
160 rdf:type schema:DefinedTerm
161 N951d18f1de1b4f708d04d5afe00f31da schema:name pubmed_id
162 schema:value 32123315
163 rdf:type schema:PropertyValue
164 N9c387d24a5234a87a0d21932f580cc70 schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 Na2f6b0831fa445f4b66a244367c36871 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Aged
168 rdf:type schema:DefinedTerm
169 Naf47afb6c62241d78bf168c86762772a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Monoamine Oxidase Inhibitors
171 rdf:type schema:DefinedTerm
172 Nbe32a2262f5a41b5be038a045d8ef090 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Female
174 rdf:type schema:DefinedTerm
175 Nc065564811414645a40fa76aead078c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neoplasm Staging
177 rdf:type schema:DefinedTerm
178 Nc6a688e6f0854e33ba66fdf5febc07f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Disease-Free Survival
180 rdf:type schema:DefinedTerm
181 Nc6e0c831680c4361a90aa2792a1cf25c rdf:first sg:person.0623540223.07
182 rdf:rest Ne75eda07eb1c43d7a2330c2db026d314
183 Nca9cd693b1b644c4847c1a89f0b8a76f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Prostatic Neoplasms
185 rdf:type schema:DefinedTerm
186 Ncdc2787cf63a4210a638871082793966 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Drug Administration Schedule
188 rdf:type schema:DefinedTerm
189 Nd4b7a58fe3fa4bdd92fd504185f2276c rdf:first sg:person.015566147707.12
190 rdf:rest N71ae5b286b4e430c88eac19d54620597
191 Ndbccb2ff16784c1bb98336a2f2e4c13f schema:name doi
192 schema:value 10.1038/s41391-020-0211-9
193 rdf:type schema:PropertyValue
194 Ne149427eb1f345f2a813134505dd6ba3 rdf:first sg:person.0600562331.16
195 rdf:rest N3631b287d1104f63b1d931eb1c8a1e04
196 Ne75eda07eb1c43d7a2330c2db026d314 rdf:first sg:person.01130633732.24
197 rdf:rest N1b637233cce044d1b1c4b6721cb80486
198 Nfb21a6044a444275a7a945a46ffe476f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Middle Aged
200 rdf:type schema:DefinedTerm
201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
202 schema:name Medical and Health Sciences
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
205 schema:name Oncology and Carcinogenesis
206 rdf:type schema:DefinedTerm
207 sg:grant.2438805 http://pending.schema.org/fundedItem sg:pub.10.1038/s41391-020-0211-9
208 rdf:type schema:MonetaryGrant
209 sg:grant.5477093 http://pending.schema.org/fundedItem sg:pub.10.1038/s41391-020-0211-9
210 rdf:type schema:MonetaryGrant
211 sg:journal.1119336 schema:issn 1365-7852
212 1476-5608
213 schema:name Prostate Cancer and Prostatic Diseases
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.488628.8
217 schema:familyName Dorff
218 schema:givenName Tanya B.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
220 rdf:type schema:Person
221 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.488628.8
222 schema:familyName Quinn
223 schema:givenName David I.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
225 rdf:type schema:Person
226 sg:person.010167317465.06 schema:affiliation grid-institutes:grid.42505.36
227 schema:familyName Gilmore
228 schema:givenName Patrick
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010167317465.06
230 rdf:type schema:Person
231 sg:person.01130633732.24 schema:affiliation grid-institutes:grid.488628.8
232 schema:familyName Agus
233 schema:givenName David B.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130633732.24
235 rdf:type schema:Person
236 sg:person.015566147707.12 schema:affiliation grid-institutes:grid.42505.36
237 schema:familyName Castellanos
238 schema:givenName Olga
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566147707.12
240 rdf:type schema:Person
241 sg:person.0600562331.16 schema:affiliation grid-institutes:grid.488628.8
242 schema:familyName Pinski
243 schema:givenName Jacek K.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16
245 rdf:type schema:Person
246 sg:person.0623540223.07 schema:affiliation grid-institutes:grid.488628.8
247 schema:familyName Gross
248 schema:givenName Mitchell E.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07
250 rdf:type schema:Person
251 sg:person.07360615242.02 schema:affiliation grid-institutes:grid.42505.36
252 schema:familyName Shih
253 schema:givenName Jean C.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07360615242.02
255 rdf:type schema:Person
256 sg:pub.10.1038/nrn1883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004025765
257 https://doi.org/10.1038/nrn1883
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/s41388-018-0325-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1104267265
260 https://doi.org/10.1038/s41388-018-0325-x
261 rdf:type schema:CreativeWork
262 grid-institutes:grid.42505.36 schema:alternateName Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
263 Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA
264 schema:name Department of Integrative Anatomical Sciences, University of Southern California, Los Angeles, CA, USA
265 Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
266 Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA
267 Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
268 rdf:type schema:Organization
269 grid-institutes:grid.488628.8 schema:alternateName Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
270 schema:name Department of Medicine, University of Southern California, Los Angeles, CA, USA
271 Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA
272 Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...